Practical insights on market access: How viable are ATMPs from an EU payer perspective?
11 Sep 2018
- Practical methods for reimbursement in a multinational network
- How are EU payers and HTA bodies viewing these therapies from a pricing perspective? Is the clinical effectiveness of CAR-T and other ATMPs justifying the cost of treatment?
- How will we fairly price single dose curative therapies?
- Can we build a new way to fund, assess and pay for these treatments together?